First Cannabinoid-Based Transdermal Patch for Chronic Pain Is Ready for Release

First Cannabinoid-Based Transdermal Patch for Chronic Pain Is Ready for Release
The first batch of the Chronic Pain CBIS Transdermal Patch will soon be released, offering a cannabinoid-based alternative to people around the globe who self-medicate for fibromyalgia and other chronic pain conditions, Cannabis Science has announced. In November 2016, the company announced the development of two new medications for pain relief in people with fibromyalgia, neuropathy, diabetic nerve pain, back strains, and other pain-related conditions. These pain relievers correspond to transdermal adhesive patches that deliver a certain dose of medication into the bloodstream by absorption through the patient’s skin. The first CBIS Transdermal Patch contains high-potency cannabinoid (CBD) extract, the second major cannabinoid in marijuana after tetrahydrocannabinol (THC). CBD has all the anti-inflammatory and pain-relieving properties without any psychoactive effects, and research has demonstrated that it can be an effective treatment for inflammatory pain. Some studies have even demonstrated that CBD might outperform traditional pain medication in some cases. “The CBIS medicated adhesive transdermal patch is placed on the skin to deliver a specific dose of cannabinoid medications into the bloodstream,” Allen Herman, chief medical officer of Cannabis Science, said in a press release. “Self-medicating patients have been reporting promoted healing effe
Subscribe or to access all post and page content.